

<b>INFORMATION DISCLOSURE CITATION</b>  <b>PTO-1449</b>				ATTORNEY'S DKT NO. 032751-027		APPLICATION NO. 09/506,942	
				APPLICANT Jean-Marc BALLOUL et al.			
				FILING DATE February 18, 2000		GROUP 1648	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
SJF	6,096,869	08/01/00	STANLEY et al.	530	351	3/22/96	
SJF	5,618,536	04/08/97	LOWY et al.	424	192.1	10/6/94	
SJF	5,855,891	06/05/99	LOWY et al.	424	192.1	11/9/97	
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
SJF	WO 96/29091	09/96	PCT				
	WO 94/24267	10/27/94	PCT				
	WO 93/00436	01/1993	PCT				
	WO 94/23037	10/1994	PCT				
	WO 93/02184	2/1993	PCT				
	WO 90/10459	9/1990	PCT				
	WO 96/00583	1/1996	PCT				
	WO 96/29091	9/1996	PCT				
SJF	WO 96/11274	4/1996	PCT				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
SJF	Zhou et al., <u>Virology</u> , 185:241-257 · 1991-						
	Heck et al., <u>PNAS USA</u> , 89:4442-4446 · 1992.						
	Galloway, 1994, "Human Papillomavirus Vaccines: A Warty Problem", <u>Infectious Agents and Disease</u> , 3:187-193						
	Hines et al., 1995, "Prospects for a Vaccine against Human Papillomavirus", <u>Obstetrics and Gynecology</u> , 86(5):860-866						
	Gajewski, 1996, "B7.1 but not B7.2 Efficiently Costimulates CD8+ T Lymphocytes in the P815 Tumor System <i>in vitro</i> ", <u>The Journal of Immunology</u> , 156:465-472						
	Crook et al., "Degradation of P53 can be Targeted by HPV E6 Sequences Distinct from those Required for P53 Binding and Transactivation", 67:547-556 · 1991.						
	Munger et al., 1989, "Complex Formation of Human Papillomavirus E7 Proteins with the Retinoblastoma Tumor Suppressor Gene Product", <u>The EMBO Journal</u> , 8:4099-4105						
SJF	International Search Report dated November 19, 1997						
EXAMINER <i>Sharon F. [Signature]</i>				DATE CONSIDERED 5/8/01			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

### THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of 1

Complete if Known

Application Number	09/506,942
Filing Date	February 18, 2000
First Named Inventor	Jean-Marc BALLOUL et. al.
Examiner Name	Sharon A. Foley
Attorney Docket Number	032751-027



#### U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
HJ	5,866,131		Ramshaw et al. 424/186.1	02-02-1999
HJ	5,866,136		Ramshaw et al. 424/197.1	02-02-1999

#### FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	
					Yes	No

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner Signature	<i>Sharon Foley</i>	Date Considered	8/30/04
--------------------	---------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.